Norethindrone (17fi-hydroxy-19-nor-17a-pregn-4-en-20-yn-3-one) and norethindrone acetate (17fl-acetoxy-19-nor-17a-pregn-4en-20-yn-3-one) interfered to a varying degree, by competitive inhibition, with the binding of progesterone and oestradiol to respective cytoplasmic receptors in the human uterus. Progesterone binding to 4S macromolecule was saturable and co-specific for progestins. Competitors like norgestrel (17f-hydroxy-18-methyl-19-nor-17a-pregn-4en-20-yn-3-one), 19-norprogesterone, medroxyprogesterone acetate (17a-acetoxy-6a-methylpregn-4ene-3,20-dione) and compound R5020 (17,21-dimethyl-19-norpregna-4,9-diene-3,20-dione) possessed higher binding affinities for the progestin receptor. The dissociation constant (Kd) for the progesterone-receptor interaction was 0.6-1.6nM and the receptor concentration ranged between 6600 and 8200 sites/ cell. Norethindrone and norethindrone acetate competed for the progesterone receptor with inhibition constants (KM) of 6.8 and 72nM respectively. Gradient displacement and competitive-receptor assays indicated that norethindrone acetate-binding affinity for progestin receptor was approximately one-tenth that of norethindrone and progesterone.
The progestins also inhibited oestradiol binding to 4.6S oestrogenic receptor by 8-12%, involving interaction at the oestradiol-binding site with a calculated K, value of0.5-0.8gM. The competitive interaction ofprogestins with steroid receptors may be of putative importance in explaining the progestin action at the target site.
Steroid-hormone receptors are the primary recognizing and regulatory molecules, functioning as biological transducers at the target site. Since uterine steroid-hormone receptors are indispensably implicated in the action of progesterone and oestradiol (Baulieu, 1975; Janne et al., 1975; O'Malley & Schrader, 1976) , any alteration in the receptorbinding properties by other compounds could modulate the processes controlled by these hormones. Previous work has shown that synthetic progestins like norethindrone (17fi-hydroxy-19-nor-17a-pregn-4-en-20-yn-3-one) and norethindrone acetate (17f,-acetoxy-19-nor-17a-pregn-4-en-20-yn-3-one) bind specifically to a uterine macromoleculewith characteristics similar to the progesterone receptor (Laumas & Kasid, 1977) . These findings prompted us to investigate whether binding of these progestins occurred at the progesterone-binding site (with inhibition kinetics of competitive type), or that the progestins interacted by binding at some other site on the receptor molecule. Further, these progestins have also been reported to interfere with the binding of oestradiol to the oestrogenic target tissues in rat (Van Kordelaar et al., 1975) . However, no quantitative data are available. As progestin-receptor interaction may be significant in the understanding of progestin action and consequently the pharmacological manipulation of cellular functioning, this interaction needed further eluciVol. 176 dation. The present work embodies the qualitative and quantitative evaluation of the interaction of norethindrone and norethindrone acetate with the receptor proteins for progesterone (pregn-4-ene-3,20-dione) and oestradiol (oestra-1,3,5(10)-triene-3,17.8-diol) Normal uterine tissue was obtained from women undergoing hysterectomy operations because of the following conditions: myomata uteri, adenomyosis and prolapsus uteri. The subjects were in the reproductive-age group (26-40 years) with normal menstrual cycles and without any hormone treatment. Immediately after hysterectomy, the uterus was cut longitudinally, adequate samples were taken for histological examination, and the pieces of tissue were chilled on ice. Further processing of samples commenced immediately at 0-20C.
Preparation ofcytosolfractions
After thorough washing, the uterine tissue was finely minced and homogenized in buffer A (0.01 MTris/HCl/0.OOl5mM-disodium EDTA, pH7.4), containing 0.012mM-thioglycerol, 20% (v/v) glycerol and 1 M-cortisol (1 1fl,17a,21-trihydroxypregn-4-ene-3,20-dione). The homogenate was centrifuged at lO50OOg for 1 h at 4°C to obtain the cytosol (supernatant) fraction. For binding assays, the cytosol was diluted with buffer A (10mg of protein/ml of cytosol) and used fresh.
Sucrose-density-gradient centrifugation
Cytosol was analysed for binding by centrifugation on linear 5-20 % (w/v) sucrose gradients, prepared in buffer A containing 10% glycerol with a Beckman gradient former. A sample (200,p) of cytosol was incubated with a lOnM solution of 3H-labelled steroid in the presence or absence of a 100-fold excess of unlabelled steroid for I h at 0°C and layered on top of the gradients. Centrifugation was carried out at 50000rev./min for 15h at 4°C in an SW 56 rotor. Bovine serum albumin (4.4S) and human y-globulin (7.1 S) were run as reference proteins in the estimation ofsedimentation coefficients by the method of Martin & Ames (1961) . Fractions (2 drops; 130,u1) were collected and A280 was recorded by using a ISCO gradient fractionator.
Quantification of3H-labelled steroid-binding sites and determination ofdissociation constant (Kd) (Scatchard analysis) Cytosol samples (100l1) were incubated with increasing concentrations of 3H-labelled steroid (0.2-12.5nM) for 12-16h at 0°C. The samples were assayed for receptor-bound radioactivity by using the dextran/charcoal adsorption technique (Korenman, 1975) . The binding data were analysed as described by Scatchard (1949) , and the correction for specific binding was made as described by Chamness & McGuire (1975 (Vendrely, 1955) .
Non-specific (non-saturable) binding was measured in parallel incubation mixtures where a 100-fold molar excess of the respective unlabelled steroid was added. It was subtracted from the total binding to obtain the specific saturable binding.
Determination of the type of inhibition (LineweaverBurk plots) Cytosol samples were incubated with increasing concentrations (0.25-lOnM) of 3H-labelled steroid alone, and also in the presence of a constant concentration of inhibitor (competitor After equilibrium was attained (12-16h), the samples were assayed for receptor-bound radioactivity by the dextran/charcoal technique. At each experimental point, control tubes with only labelled steroids at different concentrations were incubated to give the uncompeted values. All values were corrected for blank. The double-reciprocal plots of the specific-binding data were adapted from classic Lineweaver-Burk (1934) analysis. The best-fitted lines were drawn by the least-squares method. The dissociation constant (Kd) was calculated either from the slope and ordinate intercept or from the negative abscissa intercept. The number of binding sites were interpreted from the ordinate intercept.
To increase the specificity, all incubation solutions with labelled progestins also contained non-labelled 1 jM-oestradiol. Similarly all incubation solutions with labelled oestradiol also contained unlabelled 1 ,M-progesterone.
Determination ofinhibition constants (KL)
The calculated K1 values of various progestins were obtained either by using the equation for competitive inhibition or directly from Dixon plots (Dixon & Webb, 1960) .
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Determination ofrelative binding affinity
The relative binding affinities of various steroids was evaluated by their ability to compete with saturating amounts of any one of the following 3H-labelled steroids, progesterone, norethindrone or norethindrone acetate, for binding to cytosol progestin receptor.
Samples (100,ul) of cytosol were added to assay tubes containing 0.5 nM 3H-labelled steroid in 100ul of buffer A and lOOp1 of buffer A alone or containing various concentrations (0.01-100ng) of unlabelled steroid competitors. The separation of bound from free radioactive steroid was carried out at 0-2°C by using the dextran/charcoal adsorption technique.
Each assay point was determined in duplicate. All values were corrected for blanks (incubation solutions without cytosol treated with dextran/charcoal). A plot of percentage of radioactivity bound (c.p.m.) against the logarithm of the mass of the competing ligand added gave a competition curve for each ligand. The molar concentration of each competitor required to decrease the binding of 3H-labelled progestin by 50 % was calculated from these plots. The effectiveness of the competitor was calculated as described by Smith et al. (1974) .
Protein and DNA determination
Protein was determined by the method of Lowry et al. (1951) with bovine serum albumin as standard. DNA was determined by the diphenylamine method as described by Burton (1956) (Fig. 4a ) or unlabelled norethindrone (Fig. 4b) , a typical competitive inhibition was consistently observed. The concentration of progestin receptor was calculated to be about 6000 sites/cell. Determination of inhibition constants (K,) (Dixon plots [3H]oestradiol was determined by the dextran/ charcoal adsorption technique. The best-fitted lines were drawn by using the method of least squares.
20-yn-3-one), 19-norprogesterone, medroxyprogesterone acetate (17a -acetoxy -6-methylpregna -4,6-diene-3,20-dione)] or comparable with [compound R5020 (17,21-dimethyl-19-norpregna-4,9-diene-3,20-dione) , megestrol acetate (17a-acetoxy-6-methylpregna-4,6-diene-3,20-dione)] those for progesterone and norethindrone. Compound R2323 (13-ethyl-17-hydroxy-18,19-dinor-17a-pregna-4,9 ,1 1-trien-20-ynone), chlormadinone acetate (17a-acetoxy-6-chloropregna-4,6-diene-3,20-dione) and 17a-acetoxyprogesterone competed with relative affinity values ranging between 40 
Discussion
The present results convincingly demonstrate that in the human uterus progestins like norethindrone and norethindrone acetate are bound to the progesterone-recognition site, but with varying degrees of inhibition and binding constants. Froip this significant steroid-protein interaction, the action of different progestins in the human uterus via a common receptor is conceivable. Further, these progestins were also found to interfere with the binding of oestradiol to oestradiol receptor.
Studies on density-gradient centrifugation indicated that the uterine receptor, which migrated as a 4.1-4.3 S macromolecule, bound progestins in general rather than the physiological ligand progesterone. Previous work by McGuire & DeDella (1971) , Murugesan & Laumas (1973) , Verma & Laumas (1973) , Terenius (1974) , Kontula et al. (1975) and Feil et al. (1976) , demonstrating progestin-mediated displacement of progesterone binding to uterine receptor, supports our observations. However, no data are available to further characterize the type of inhibition obtained with the progestins. Our results involving competitive-receptor assays, which have been evaluated by the double-reciprocal plots, unequivocally demonstrate the existence of a competitive mechanism between the progestins and progesterone for the same binding site on the receptor. The interpretation becomes more plausible in that a putative intracellular receptor has been characterized for norethindrone and norethindrone acetate, with physicochemical and kinetic behaviour very similar to that of uterine progesterone receptor (Laumas & Kasid, 1977) . Further, these progestins also inhibited oestradiol binding to oestrogenic receptor, but only to the extent of 8-12%. The decrease in the uptake of [3H]oestradiol in the presence of norethynodrel (Laumas et al., 1972) , chlormadinone acetate (Rosner et al., 1972) and norethindrone/norethindrone acetate (Van Kordelaar et al., 1975) has been well demonstrated. In the present study, this progestin-oestradiol interaction was investigated at the receptor level, giving adequate attention to the specific and nonspecific binding. It appeared that these progestins inhibited oestradiol binding by competitively modulating the receptor activity.
Receptor affinity is of prime importance in studies of kinetics and biological proffle of the drugs. Laumas, unpublished work) and a high conversion into norethindrone (with strong receptor affinity). Ligand specificity data yielded some valuable information on the structural requirements for efficient binding to progestin receptor, and supported the earlier observations by Liao et al. (1973) , Smith et al. (1974) and Kontula et al. (1975) . In general a 3-oxo-4-ene structure is required for effective binding. Modifications of the planar structures of the A/B ring of steroid decreased the binding significantly. The orientation of the 17fl-hydroxy group and as a consequence its hydrogen-bond geometry and the directional interaction of the 17-ethynyl group were directly linked to the binding mechanism of progestin on the uterine receptor. The absence of a C-19 methyl group (19-norsteroids) facilitated the binding considerably. However, the introduction of an additional 18-methyl group in d-norgestrel showed dramatic enhancement in the binding. The esterification of the 17a-hydroxy function leads to a substantial increase in the binding affinity. However, the introduction of an acetate group at the 171i-position disrupted the steroid binding considerably.
The conclusive evidence in the present paper that the progestins bind to the progesterone-binding site on the receptor, and also inhibit the oestradiol binding, is of considerable significance. It is well known that oestradiol prepares the uterus for progesteroneaction, and progesterone is necessary for the implantation. Studies with a single silastic implant (Bhatnagar et al., 1 975; indicate that norethindrone acetate released in micro quantities does not appear to interfere with ovulation in the earlier months, but suppresses ovulation during the later months ofuse. The contraceptive effect, when ovulation is not suppressed, could probably result from the progestin action at some other site, like uterus. Thus the interaction of these progestins with the receptors for progesterone and oestradiol, either by simple competition or by change in the relative spatial orientation at the active site, would change the receptor availability, leading to modulation of hormone-dependent changes. This would critically influence uterine 'receptivity' to hormonal stimuli and and thus account for the contraceptive action.
